Drug Trial Radar · NCT02658929
Study of bb2121 in Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Jan 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
67
Actual
Start
Dec 22, 2015
Primary completion
Jul 22, 2019
Study completion Sep 22, 2022
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Genetix Biotherapeutics Inc.
- First posted
- Jan 20, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed/refractory multiple myeloma (MM).
Conditions
- Multiple Myeloma
Interventions
bb2121Biological
bb2121
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs) and abnormal laboratory test results, including dose limiting toxicities (DLTs)Time frame: Day 1 through Month 60
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Stanford Cancer Center
Stanford, California
National Cancer Institute
Bethesda, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Hackensack University Medical Center
Hackensack, New Jersey
Mt. Sinai Medical Center Division of Hematology/Oncology
New York, New York
Sarah Cannon Research Inst
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.